GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicio Therapeutics Inc (NAS:ELTX) » Definitions » FCF Yield %

Elicio Therapeutics (Elicio Therapeutics) FCF Yield % : -32.47 (As of May. 21, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Elicio Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Elicio Therapeutics's Trailing 12-Month Free Cash Flow is $-36.73 Mil, and Market Cap is $101.27 Mil. Therefore, Elicio Therapeutics's FCF Yield % for today is -32.47%.

The historical rank and industry rank for Elicio Therapeutics's FCF Yield % or its related term are showing as below:

ELTX' s FCF Yield % Range Over the Past 10 Years
Min: -105.47   Med: 0   Max: 0
Current: -32.47


ELTX's FCF Yield % is ranked worse than
68.27% of 1557 companies
in the Biotechnology industry
Industry Median: -14.1 vs ELTX: -32.47

Elicio Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.


Elicio Therapeutics FCF Yield % Historical Data

The historical data trend for Elicio Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicio Therapeutics FCF Yield % Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
- - - - -40.90

Elicio Therapeutics Quarterly Data
Dec19 Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -47.68 -29.54 -49.42 -62.10

Competitive Comparison of Elicio Therapeutics's FCF Yield %

For the Biotechnology subindustry, Elicio Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elicio Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Elicio Therapeutics's FCF Yield % falls into.



Elicio Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Elicio Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-32.76 / 80.0950248
=-40.90%

Elicio Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-12.122 * 4 / 78.0824
=-62.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elicio Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Elicio Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Elicio Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Elicio Therapeutics (Elicio Therapeutics) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA, USA, 02139
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.
Executives
Yekaterina Chudnovsky director C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Robert R Ruffolo director
Peter Demuth officer: Chief Scientific Officer C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Assaf Segal director C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Annette Matthies officer: Chief Business Officer ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139
Robert Connelly director, officer: CEO, President and Director 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Julian Adams director C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116
Christopher Haqq officer: See Remarks C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Carol Gail Ashe director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Brian Piekos officer: Chief Financial Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Gregory S Curhan officer: See Remarks 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Itzhak Goldberg officer: See Remarks 51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
John F. Neylan officer: See Remarks 750 LEXINGTON AVENUE, NEW YORK NY 10022

Elicio Therapeutics (Elicio Therapeutics) Headlines

From GuruFocus

Elicio Therapeutics Reports Inducement Grants

By Marketwired 08-22-2023